2026-04-17T02:06:58Zhttps://recercat.cat/oai/requestoai:recercat.cat:11351/123812025-10-24T10:25:25Zcom_2072_378070com_2072_378040col_2072_378092
RECERCAT
author
Neyra, Adrián
author
Parro-Torres, Carlos
author
Carrera, Indalecio
author
Echarri, Eduardo
author
Torrens, Marta
author
ROS-CUCURULL, ELENA
2025-10-24T10:25:24Z
2025-10-24T10:25:24Z
2025-01-08T11:25:34Z2025-01-08T11:25:34Z2024-10-30
http://hdl.handle.net/11351/12381
Care management; Schizophrenia; Substance use disorderGestió assistencial; Esquizofrènia; Trastorn per consum de substànciesGestión asistencial; Esquizofrenia; Trastorno por consumo de sustanciasBackground
Schizophrenia and substance use disorders (SUDs) are often comorbid conditions that present clinical challenges due to their heterogeneity and the difficulties associated with poor physical health, low medication adherence, high relapse and hospitalization rates, and increased risk of mortality. This is often exacerbated by a fragmented health care system that treats addiction and mental illness separately, leading to delays in proper diagnosis and treatment.
Main text
The aim of this narrative review, based on an extensive literature search and experts’ clinical experience, is to synthesize evidence on the psychopathological and clinical characteristics of patients, the burden and management at the level of healthcare system, and possible gaps in the treatment of schizophrenia with comorbid SUD in order to understand and address the needs of patients. Treatment options, differences between antipsychotic medications, and the benefits of long-acting formulations and partial dopaminergic agonists are described. Partial dopamine agonists (aripiprazole, cariprazine, and brexpiprazole) have demonstrated good control of psychotic symptoms and SUDs with a favorable safety profile.
Conclusion
Pharmacological interventions should be accompanied by psychosocial support within an integrated and multidisciplinary approach that promotes shared decision-making and a good therapeutic alliance between the entire medical team and the patient.The elaboration of the manuscript was supported by Otsuka Pharmaceutical S.A. and Lundbeck España S.A.
Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess
Esquizofrènia - Tractament
Diagnòstic dual
Abús de substàncies
Antipsicòtics
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Diagnosis, Dual (Psychiatry)
PSYCHIATRY AND PSYCHOLOGY::Mental Disorders::Schizophrenia Spectrum and Other Psychotic Disorders::Schizophrenia
PSYCHIATRY AND PSYCHOLOGY::Mental Disorders::Substance-Related Disorders
HOMEOPATHY::Homeopathic Therapeutics::Classification of Homeopathic Remedies::Homeosycosics
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Clinical Decision-Making
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::diagnóstico dual psiquiátrico
PSIQUIATRÍA Y PSICOLOGÍA::trastornos mentales::espectro de la esquizofrenia y otros trastornos psicóticos::esquizofrenia
PSIQUIATRÍA Y PSICOLOGÍA::trastornos mentales::trastornos relacionados con sustancias
HOMEOPATÍA::terapéutica homeopática::clasificación de los remedios homeopáticos::homeosicósicos
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::toma de decisiones clínicas
Management of schizophrenia and comorbid substance use disorders: expert review and guidance
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion